Flem­ming Ørn­skov takes on a new chal­lenge, dri­ving a $10B der­ma­tol­ogy spin­out with some big plans for growth

Just as Gal­der­ma was be­ing spun out of Nestlé with plans to be­come the biggest in­de­pen­dent der­ma­tol­ogy com­pa­ny on the plan­et, they signed a new, high pro­file CEO and CFO who have built their rep­u­ta­tions around dri­ving growth at Shire, set­ting the stage for a $62 bil­lion Take­da buy­out.

Thomas Dit­trich

Flem­ming Orn­skov and Thomas Dit­trich, who shook up Shire — hard — to make it in­to a top play­er in rare dis­eases and oph­thal­mol­o­gy, took the two top spots at Gal­der­ma, which of­fi­cial­ly re­brand­ed from Nestlé Skin Health a week ago fol­low­ing a 10.2 bil­lion CHF deal.

Stu­art Raet­z­man, Nestlé Skin Health’s CEO for the past 3 years, switched to a di­rec­tor’s role.

Orn­skov had this to say about his new post:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER